We are experiencing some temporary issues. The market data on this page is currently delayed.
NasdaqGS – Delayed Quote USD
178.91 +2.90 (+1.65%)
At close: May 1 at 4:00:01 PM EDT
178.79 -0.12 (-0.07%)
After hours: May 1 at 7:49:27 PM EDT
- Previous Close
176.01 - Open
178.00 - Bid 177.60 x 500
- Ask 179.82 x 500
- Day’s Range
174.98 – 179.37 - 52 Week Range
122.00 – 208.31 - Volume
840,304 - Avg. Volume
1,312,164 - Market Cap (intraday)
12.813B - Beta (5Y Monthly) 1.81
- PE Ratio (TTM)
30.02 - EPS (TTM)
5.96 - Earnings Date (est.) Jul 29, 2026
- Forward Dividend & Yield —
- Ex-Dividend Date —
- 1y Target Est
209.00
Trailing total returns as of 5/1/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Valuation Measures
As of 4/30/2026
-
Market Cap
12.61B
-
Enterprise Value
11.63B
-
Trailing P/E
29.58
-
Forward P/E
15.62
-
PEG Ratio (5yr expected)
0.93
-
Price/Sales (ttm)
3.10
-
Price/Book (mrq)
3.04
-
Enterprise Value/Revenue
2.84
-
Enterprise Value/EBITDA
18.68
Financial Highlights
Profitability and Income Statement
-
Profit Margin
10.50%
-
Return on Assets (ttm)
7.47%
-
Return on Equity (ttm)
10.82%
-
Revenue (ttm)
4.1B
-
Net Income Avi to Common (ttm)
429.89M
-
Diluted EPS (ttm)
5.96
Balance Sheet and Cash Flow
-
Total Cash (mrq)
1.06B
-
Total Debt/Equity (mrq)
2.01%
-
Levered Free Cash Flow (ttm)
584.22M
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
-
Align Earnings: Strong Volume Growth and Flat Pricing Signal Stability; Shares Still Look Cheap
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients’ teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
-
Lowering target price to $199.00
ALIGN TECHNOLOGY INC has an Investment Rating of BUY; a target price of $199.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of High.
-
Align Earnings: Solid Year-End Results From Strong Shipments, Margin Gain Boosts Investor Confidence
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients’ teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
-
Raising target price to $219.00
ALIGN TECHNOLOGY INC has an Investment Rating of BUY; a target price of $219.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of High.
